 |
Indication & Dosage |
| |
| |
| Oral |
| METASTATIC TESTICULAR TUMOURS |
| Adult:
20 mg/m2 BSA daily for 5 days every 3-4 wk. |
| |
| Oral |
| METASTATIC OVARIAN AND BLADDER CANCER |
| Adult:
For monotherapy, 50-120 mg/m2 as a single dose infused in 0.9% sodium chloride or glucose given every 3-4 wk. Alternatively, 20 mg/m2 daily for 5 days every 3-4 wk. For combination therapy, lower doses are used. |
|
| |
|
| Precautions |
Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. |
| |
|
| Adverse Drug Reactions |
Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities. |
| |
|
| Interactions |
Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ≤100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression. |
| |
|
|
|
